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Abstract We have designed a new class of oligonucleotides,
‘dumbbell RNA/DNA chimeric oligonucleotides’, consisting of a
sense RNA sequence and its complementary antisense DNA
sequence, with two hairpin loop structures. The reaction of the
nicked (NDRDON) and circular (CDRDON) dumbbell RNA/
DNA chimeric oligonucleotides with RNase H gave the
corresponding antisense phosphodiester oligodeoxynucleotide
together with the sense RNA cleavage products. The liberated
antisense phosphodiester oligodeoxynucleotide was bound to the
target RNA, which gave RNA cleavage products by treatment
with RNase H. The circular dumbbell RNA/DNA chimeric
oligonucleotide showed more nuclease resistance than the linear
antisense phosphodiester oligonucleotide (anti-ODN) and the
nicked dumbbell RNA/DNA chimeric oligonucleotide. The
CDRDON with four target sites (influenza virus A RNA
polymerases (PB1, PB2, PA) and nucleoprotein (NP)) was
synthesized and tested for inhibitory effects by a CAT-ELISA
assay using the clone 76 cell line. The circular dumbbell DNA/
RNA chimeric oligonucleotide (CDRDON-PB2-as) containing
an AUG initiation codon sequence as the target of PB2 showed
highly inhibitory effects.
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1. Introduction
Antisense oligonucleotides have been used to regulate gene
expression [1^4]. Unmodi¢ed (phosphodiester) antisense oli-
gonucleotides have been reported to have an inhibitory e¡ect
against HIV-1 [5,6]. Unmodi¢ed oligonucleotides, in particu-
lar, have limited survival in vitro and in vivo. These oligonu-
cleotides are degraded by nucleases present in serum and in
cells [7,8]. Antisense oligonucleotides with phosphorothioate
backbones exhibit several advantages over the other forms,
including relatively high nuclease resistance and the capacity
to induce the degradation of the target sequence by RNase H
[9,10]. However, phosphorothioate oligonucleotides hybridize
more weakly with the complementary nucleic acids than the
unmodi¢ed oligonucleotides and are eventually degraded, pri-
marily from the 3P end. Phosphorothioate oligonucleotides
have also been shown to block the proliferation of HIV-1 in
acutely infected cells in a non-sequence-speci¢c manner [11],
probably by the inhibition of reverse transcriptase [12,13] and/
or the viral entry process [14,15]. Another problem in the use
of antisense phosphorothioate oligonucleotide is their ine⁄-
cient cellular uptake. One approach to these problems has
been the development of modi¢ed antisense oligonucleotides
with PNO groups in the internucleotide bonds. In addition,
the degradation of phosphodiester oligonucleotides can be
slowed considerably by blocking 3P or 3P and 5P ends of the
chain, because the primary degrading enzymes present in cells
are the 3P-exonuclease type [16,17]. Several stabilization meth-
ods for the phosphodiester oligonucleotides have been pro-
posed, such as the incorporation of various chemical substitu-
ents at the 3P-hydroxyl groups [16^18], the circularization of
the oligonucleotides by joining the 3P and the 5P ends [19^21],
and the formation of a hairpin loop structure at the 3P end
[22,23]. The circular dumbbell DNA oligonucleotides have
biological relevance as aptamers or decoys for hybridizing
proteins such as transcription factors [24,25].
In this paper, we describe the design of a new class of
oligonucleotides, ‘dumbbell RNA/DNA chimeric oligonucleo-
tides’, consisting of a sense RNA sequence and its comple-
mentary antisense DNA sequence, with two hairpin loop
structures. These oligonucleotides have increased nuclease re-
sistance and cellular uptake. The antisense phosphodiester
deoxyoligonucleotide is liberated by RNase H treatment of
the dumbbell RNA/DNA chimeric oligonucleotides. We
have also tested the inhibition of in£uenza virus RNA polym-
erase and nucleoprotein gene expression by dumbbell RNA/
DNA chimeric phosphodiester as determined by CAT protein
expression (CAT activity), in the clone 76 cell line [26,27].
2. Materials and methods
2.1. Oligonucleotide synthesis
The oligonucleotides were synthesized by means of the phosphor-
amidite approach using an Applied Biosystems DNA synthesizer,
Model 392. The 5P-phosphorylated oligonucleotides were synthesized
using a dimethoxytrityl-hexa-ethyloxy-glycol-2-cyanoethyl-N,N-diiso-
propyl phosphoramidite as the phosphorylating agent. The oligonu-
cleotide derivatives were puri¢ed by polyacrylamide gel electrophore-
sis or by reverse phase HPLC chromatography. The extinction
coe⁄cients of the oligonucleotides were determined by calculating
the theoretical extinction coe⁄cients as the sum of the nucleosides
and multiplying with the experimentally determined enzymatic hypo-
chromicity. The 5P-phosphorylated nicked dumbbell RNA/DNA chi-
meric oligonucleotide (0.2 A260) was incubated in 10 Wl of 50 mM
Tris-HCl, pH 7.5, and 10 mM MgCl2 at 90‡C for 5 min, and then
at 15‡C for 2 min. The solution was incubated with 1 Wl of 100 mM
dATP, 1 Wl of 25 Wg BSA per ml, and 40 units of T4 DNA ligase at
37‡C for 30 min. The reaction mixture was extracted with an equal
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volume of water-saturated chloroform/phenol (1:1, v/v), and was pre-
cipitated with ethanol. The circular oligonucleotides were puri¢ed by
denaturing PAGE (20% polyacrylamide containing 7 M urea). The
band corresponding to the desired oligonucleotide was eluted from the
gels with water, and was precipitated with ethanol. The identity of
each of the ligated dumbbells was veri¢ed by phosphodiesterase pro-
tection mapping.
2.2. Nuclease stability of nicked and circular dumbbell RNA/DNA
chimeric oligonucleotides
To determine the resistance of the oligonucleotides to nucleases in
fetal bovine serum, the oligonucleotides (0.2 A260) were incubated with
200 Wl of culture medium containing 10% fetal bovine serum for 16 h
at 37‡C. Aliquots were taken at 0, 3, 6, 12, and 24 h and were
analyzed by PAGE (20% polyacrylamide containing 7 m urea). Den-
sitometric analysis of gels stained with silver nitrate was performed on
a Millipore BioImage 60 S.
2.3. RNase H activity
The 45 mer RNA (5P-UGUUUCACAACAAAAGCCUUAGG-
CAUCUCCAUGGCAGGAGAAG-3P) (1 pmol) was mixed with oli-
gonucleotides (10 pmol) in 30 Wl of 20 mM Tris-HCl (pH 7.5), 10 mM
MgSO4, 0.1 mM DTT, and 100 mM KCl. RNasin (40 units) and
Escherichia coli RNase H (0.5 Wl, 0.4 units) were added to the mixture,
which was incubated at 37‡C. Aliquots were taken at 0, 1, 2, and 4 h,
and were analyzed by PAGE (20% polyacrylamide containing 8.3 M
urea). Densitometric analysis of gels stained with silver nitrate was
performed on a Millipore BioImage 60 S.
2.4. Cellular uptake of 32P-labeled nicked and circular dumbbell
RNA/DNA chimeric oligonucleotides
The 5P ends of the nicked dumbbell RNA/DNA chimeric oligonu-
cleotide were labeled with [Q-32P]dATP and T4 polynucleotide kinase
in bu¡er containing 100 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 10
mM DTT, 0.2 mM spermidine, and 0.2 mM EDTA at 37‡C for 30
min. The labeled oligonucleotides were puri¢ed by denaturing PAGE
(20% polyacrylamide containing 7 M urea). The band corresponding
to the desired oligonucleotide was eluted from the gels with water, and
precipitated with ethanol. The circularization of the 5P-phosphoryl-
ated nicked dumbbell RNA/DNA chimeric oligonucleotide to give
the circular dumbbell RNA/DNA chimeric oligonucleotide was car-
ried out as described above, and then the oligonucleotide was puri¢ed
using a Quick spin column (G-25). MDCK cells were diluted to
1U105 cells/ml in RPMI 1640 medium containing 10% heat-inacti-
vated FCS and were dispensed in 24 multi-well plates. After a 48 h
incubation at 37‡C in a CO2 incubator, the RPMI 1640 medium was
changed. The cells were further incubated with the 3P end-labeled
oligomers for the stated periods. After washing the cells four times
with chilled phosphate-bu¡ered saline (PBS), the cells were pelleted by
centrifugation and were lysed in 0.5 ml of 1% sodium dodecyl sulfate
(SDS). The cell associated radioactivity was determined by liquid
scintillation counting and is expressed as pmol/105 cells.
2.5. Cells
The murine C127 derivative cell line, clone 76 [26,27], was grown in
Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS).
2.6. In vitro RNA synthesis
The plasmid pOUMS101 contains the CAT gene sandwiched be-
tween the 5P- and 3P-terminal sequences of the cDNA encoding RNA
segment 8 of in£uenza virus A/PR/8/34 in the antisense orientation of
the T7 RNA polymerase [28]. Transcription of MboII-digested
pOUMS101 by T7 RNA polymerase results in the synthesis of the
antisense CAT RNA. The template DNA was removed by treatment
with DNase I. The RNA transcript was puri¢ed by TBE/7 M urea,
5% polyacrylamide gel electrophoresis, elution, and ethanol precipita-
tion in the presence of 3 M sodium acetate.
2.7. RNA transcription of clone 76 cells
Clone 76 cells, grown in 60 mm dishes and approximately 50%
con£uent, were treated with 1036 M dexamethasone in DMEM
containing 10% FCS at 37‡C. After 24 h, the cells were washed
with PBS, a mixture of oligonucleotides and 5 Wg of lipofection re-
agent (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium-
methylsulfate; DOTAP, Boehringer Mannheim) in DMEM was
added, and the cells were incubated for 4 h at 37‡C. The cells were
washed with PBS, 100 ng of RNA was mixed with 5 Wg of DOTAP in
DMEM, and the mixture was incubated for 4 h at 37‡C. The medium
was changed to fresh DMEM containing 10% FCS and the cells were
incubated for a further 20 h. The amount of CAT protein in the cells
was monitored by the CAT assay kit (anti-CAT-DIG, Boehringer
Mannheim).
3. Results and discussion
3.1. Nuclease sensitivities of nicked and circular dumbbell
RNA/DNA chimeric oligonucleotides
The nuclease sensitivities of the nicked (NDRDON) and the
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Fig. 1. The structures and sequences of the oligonucleotides used in
this study and described in the text. Capital letters: DNA; small let-
ters: RNA. The antisense sequences are underlined. Targeted RNA:
3P to 5P (italics); synthetic oligonucleotides: 5P to 3P. Abbreviations:
as, antisense sequence; ran, random sequence.
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circular (CDRDON) dumbbell RNA/DNA chimeric oligonu-
cleotides with the RNA-DNA base pairs (sense (RNA) and
antisense (DNA)) in the double helical stem were studied in
fetal bovine serum (Fig. 2). For comparison, the anti-ODN
and the anti-S-ODN were chosen as controls. The results ob-
tained by incubating the circular dumbbell oligonucleotides in
fetal bovine serum provided additional evidence of their rela-
tive stability (Fig. 2). The CDRDON was stable (90%) after
24 h of incubation, whereas the anti-S-ODN was stable (76%)
after 24 h. The NDRDON and the anti-ODN were completely
degraded (100%) after 12 h. In the fetal bovine serum assay,
the circular dumbbell oligonucleotide was converted to an
open circular oligonucleotide by running on denaturing
PAGE (20% polyacrylamide containing 8.3 M urea), and it
remained stable after 24 h when the circular dumbbell oligo-
nucleotide was converted to the nicked dumbbell oligonucleo-
tide, it was quickly digested. The stability of the oligonucleo-
tides was increased with two hairpin loop structures with
RNA-DNA base pairs (sense-RNA and antisense-DNA) in
the stem at the 3P and 5P ends.
3.2. Duplex hybridization
The hybridization between antisense-DNA and sense-RNA
in the dumbbell RNA/DNA chimeric phosphodiester oligonu-
cleotides is the key to the nuclease resistance in vitro as well as
in vivo. We measured the melting temperature of oligonucleo-
tides with either antisense phosphodiester (anti-ODN) or
phosphorothioate (anti-S-ODN) bonds with the complemen-
tary sense phosphodiester oligodeoxyribonucleotide (sens-
ODN) and oligoribonucleotide (sens-RNA) (Fig. 1). The Tm
values of the duplexes of the phosphodiester anti-ODN with
the phosphodiester sens-ODN and the sens-RNA were 40‡C
and 41‡C, respectively (Table 1). The Tm values of the du-
plexes of the phosphorothioate anti-S-ODN with the phos-
phodiester sens-ODN and the sens-RNA were 33‡C and
28‡C, respectively (Table 1). The antisense oligonucleotides
(anti-ODN) containing the phosphorothioate bonds hybrid-
ized more weakly with the complementary nucleic acids than
the unmodi¢ed oligonucleotides. Next, we measured the melt-
ing temperatures of the nicked (NDRDON) and the circular
(CDRDON) dumbbell RNA/DNA chimeric oligonucleotides.
The Tm values of the NDRDON and the CDRDON were
47‡C and 81‡C, respectively. The nicked (NDRDON) and
the circular dumbbell (CDRDON) DNA/RNA chimeric oli-
gonucleotides had higher Tms than the DNA-DNA and
DNA-RNA duplexes. Furthermore, the circular oligonucleo-
tide (CDDDON) with the DNA-DNA base pairs (sense
(DNA) and antisense (DNA)) in the double helical stem has
an estimated Tm of 71‡C, which is 10‡C less than the Tm of
the CDRDON. These results suggest that the stability of the
oligonucleotides also increased with the introduction of the
two hairpin loop structures to the RNA-DNA base pairs
(sens (RNA) and antisense (DNA)) in the double helical stem.
Next, we measured the melting temperatures of the oligo-
nucleotides bound with the complementary 45-mer RNAs (5P-
UGUUUCACAACAAAAGCCUUAGGCAUCUCCAUG-
GCAGGAGAAG-3P) (Table 1, Fig. 1). The Tm value of the
duplex between the anti-ODN and the 45-mer RNA was
55‡C. On the other hand, when the double-stranded DNA
(anti-ODN/sens-ODN) was mixed with the 45-mer RNA,
two transitions were observed: one, at 53‡C, which was typ-
ical of the duplex between the anti-ODN and the 45-mer
DNA, and one, at 41‡C, which coincided with the double-
stranded DNA. The Tms of the duplexes between the nicked
dumbbell RNA/DNA chimeric oligonucleotide (NDRDON)
and the 45-mer RNA approached the Tm values of the duplex
between the anti-ODN and the 45-mer RNA (51‡C). In con-
trast, the circular (CDRDON) dumbbell RNA/DNA chimeric
oligonucleotides did not undergo two transitions (Table 1).
Furthermore, when the amount of the 45-mer RNA was in-
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Fig. 2. Digestion of the antisense oligonucleotide and nicked, and circular dumbbell RNA/DNA chimeric oligonucleotides in the presence of
10% calf serum at 37‡C for 0^24 h. Percentages of the anti-ODN, anti-S-ODN, NDRDON, and CDRDON are shown as open squares, solid
circles, solid squares, and open circles, respectively. Data represent average values of at least three di¡erent experiments.
Table 1















aValues were obtained in 10 mM sodium phosphate bu¡er and 10
mM NaCl at pH 7.0.
bThis reaction was carried out in the presence of 5 molar equivalent of
the target 45-mer RNA.
cData represent average values of at least three di¡erent experiments.
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creased up to ¢ve molar equivalent under the above condi-
tions, the Tms of the duplexes between the nicked dumbbell
RNA/DNA chimeric oligonucleotide (NDRDON) and the 45-
mer RNA approached the Tm value of the duplex between the
anti-ODN and the 45-mer RNA (52‡C). These results suggest
that the nicked dumbbell oligonucleotides were only partially
bound to the complementary RNA. However, the Tm value of
the duplex between the circular dumbbell RNA/DNA chimer-
ic oligonucleotide (CDRDON) and the 45-mer RNA is 81‡C,
which is typical of the CDRDON. In particular, the circular
dumbbell RNA/DNA chimeric oligonucleotide with the high-
er Tm value showed more nuclease resistance than the linear
antisense phosphodiester oligonucleotide and the nicked
RNA/DNA chimeric oligonucleotide (Fig. 1 and Table 1).
3.3. RNase H treatment of the dumbbell RNA/DNA chimeric
oligonucleotides
The RNase H-mediated liberation of antisense phospho-
diester oligodeoxynucleotides from the dumbbell RNA/DNA
chimeric oligonucleotides was studied. The RNase H activity
assay was carried out with the target 45-mer RNA and either
the circular (CDRDON) or the nicked (NDRDON) dumbbell
RNA/DNA chimeric oligonucleotides in the presence of E.
coli RNase H for up to 4 h (Fig. 3). The antisense phospho-
diester oligodeoxynucleotide (anti-ODN) was used for com-
parison, as the control oligonucleotide (Fig. 3, lanes 3^6). The
target 45-mer RNA with the anti-ODN was completely
cleaved by E. coli RNase H within 4 h (Fig. 3, lane 6). On
the other hand, the reaction of the NDRDON with RNase H
gave the corresponding antisense phosphodiester oligodeoxy-
nucleotide together with the RNA cleavage product (Fig. 3,
lane 8). The target 45-mer RNA was then added to the above
reaction, which produced the characteristically shortened
RNA fragments (Fig. 3, lanes 9^11). After 4 h, the target
45-mer RNA was almost completely cleaved (90%) to the
shortened RNA fragments (Fig. 3, lane 11). Furthermore,
when the circular dumbbell RNA/DNA chimeric oligonucleo-
tide (CDRDON) was used in place of the NDRDON, under
the same conditions as described above, RNA template cleav-
age was observed (62%) (Fig. 3, lanes 14^16). In the case of
the CDRDON, the reaction of the CDRDON with RNase H
gave 100% of the corresponding antisense phosphodiester oli-
godeoxynucleotide together with the RNA cleavage product
within 4 h (Fig. 3, lane 13). The RNase H cleavage rate for
the target 45-mer RNA with the circular dumbbell RNA/
DNA chimeric oligonucleotide (CDRDON) is slower than
those for the nicked dumbbell RNA/DNA chimeric oligonu-
cleotide (NDRDON) and the linear antisense oligonucleotides
(anti-ODN and anti-S-ODN). However, after 6 h, the target
45-mer RNA with the circular dumbbell RNA/DNA chimeric
oligonucleotide (CDRDON) was completely degraded by E.
coli RNase H (Fig. 3, lane 17). The liberated antisense phos-
phodiester oligonucleotide is bound to the target mRNA; that
is, the inhibition of viral replication occurs in a sequence-spe-
ci¢c manner without the inhibition of RNase H activity. In
contrast, the antiviral activity of the phosphorothioate oligo-
nucleotide (S-ODN) is due to a direct e¡ect of reverse tran-
scriptase [12,13] and/or the viral entry process [14,15].
3.4. Cellular uptake of dumbbell RNA/DNA chimeric
oligonucleotides
Oligonucleotides have been used as antisense inhibitors of
gene expression in various culture systems and are considered
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Fig. 3. Speci¢c cleavage by RNase H of the target 45-mer RNA in the presence of the dumbbell RNA/DNA chimeric oligonucleotides
(NDRDON and CDRDON), and the anti-ODN. Lane 1, control: 45-mer RNA; lane 2, control: 45-mer RNA/RNase H/4 h; lane 3, control:
anti-ODN/45-mer RNA; lane 4, anti-ODN/45-mer RNA/RNase H/1 h; lane 5, anti-ODN/45-mer RNA/RNase H/2 h; lane 6, anti-ODN/45-mer
RNA/RNase H/4 h; lane 7, control: NDRDON/45-mer RNA (faster run: NDRDON; slower run: 45-mer RNA); lane 8, control: NDRDON/
RNase H/4 h (liberated anti-ODN from NDRDON); lane 9, NDRDON/45-mer RNA/RNase H/1 h (faster migrating band: liberated anti-
ODN; slower migrating band: NDRDON; ladder bands: RNA cleavage product); lane 10, NDRDON/45-mer RNA/RNase H/2 h; lane 11,
NDRDON/45-mer RNA/RNase H/4 h; lane 12, control: CDRDON/45-mer RNA; lane 13, control: CDRDON/RNase H/4 h (liberated anti-
ODN from CDRDON); lane 14, CDRDON/45-mer RNA/RNase H/1 h (faster migrating band: CDRDON; intermediate migrating band: lib-
erated anti-ODN; slower migrating band: 45-mer RNA); lane 15, CDRDON/45-mer RNA/RNase H/2 h; lane 16, CDRDON/45-mer RNA/
RNase H/4 h (faster migrating band: liberated anti-ODN; slower migrating band: 45-mer RNA; ladder bands: RNA cleavage product); lane
17, CDRDON/45-mer RNA/RNase H/6 h.
Table 2
Inhibition of in£uenza virus RNA polymerase and nucleoprotein
gene expression by the circular dumbbell RNA/DNA chimeric oligo-
nucleotides
Oligomera Inhibitory e¡ect (%)b;c
0.03 WM 0.3 WM 1.0 WM
CDRDON-PB2-as 36 60 79
S-ODN-PB2-as 33 42
CDRDON-PB2-ran 6 5 19
CDRDON-PB1-as 6 5 15 21
CDRDON-PB1-ran 6 5 6 5
CDRDON-PA-as 18 26 39
CDRDON-PA-ran 6 5 10
CDRDON-NP-as 17 30 35
CDRDON-NP-ran 6 5 9
aThe antisense sequences are described in Fig. 1.
bThe inhibitory e¡ects are given as the percentage inhibtion of CAT
protein expression, and are compared and normalized to 100% CAT
protein expression.
cData represent average values of at least three di¡erent experiments.
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to be potential therapeutic agents against cancer and viral
infections. In order to exert any of these e¡ects, the oligonu-
cleotides must enter the cytoplasmic and nuclear compart-
ments of the cells. The problem in the use of antisense oligo-
nucleotides is that the cellular uptake of oligonucleotides is
ine⁄cient [29,30]. Immunoliposomes have been studied as a
transport system to deliver both membrane-permeable and
impermeable molecules into cells [31,32]. However, in contrast
to the use of endogenously transcribed or microinjected anti-
sense oligonucleotides, regulatory activity of exogenous oligo-
nucleotides appears to depend upon the uptake of su⁄cient
amounts by cells. As shown in Fig. 4, the 32P-labeled
CDRDON strongly associated with the MDCK cells, but
the 32P-labeled NDRDON did not. The cell-associated radio-
activity was negligible in the MDCK cells treated with the
32P-labeled anti-ODN. On the other hand, the 32P-labeled
anti-S-ODN also strongly associated with the MDCK-4 cells.
The cell-associated radioactivity in the MDCK cells treated
with the 32P-labeled CDRDON increased rapidly and reached
a plateau after 60 min of treatment, and the NDRDON and
anti-ODN oligomers yielded about 12-fold lower cell-associ-
ated counts than the CDRDON. A high level of cell-associ-
ated anti-S-ODN was observed. The circularization resulting
from the joining of the 3P and the 5P ends of the RNA/DNA
chimeric oligonucleotides containing two hairpin loop struc-
tures increases the cellular uptake, as compared with the
nicked dumbbell RNA/DNA chimeric oligonucleotide
(NDRDON) and the linear antisense phosphodiester oligonu-
cleotides (anti-ODN).
3.5. Inhibition of in£uenza virus RNA polymerase and
nucleoprotein gene expression by circular dumbbell
RNA/DNA chimeric oligonucleotides
We have also tested the inhibition of in£uenza virus RNA
polymerase and nucleoprotein gene expression by circular
dumbbell RNA/DNA chimeric oligonucleotides as determined
by CAT protein expression (CAT activity), in the clone 76 cell
line [26,27]. The CDRDON containing antisense sequences as
targets of PB1, PB2, PA, and NP, and random sequences with
the same base composition as the four targets are illustrated in
Fig. 1. The in vitro activities of these oligonucleotides on the
expression of the in£uenza virus RNA polymerase and nucle-
oprotein genes were assessed on the basis of their inhibition of
CAT protein expression with the CAT-ELISA method. The
circular dumbbell RNA/DNA chimeric oligonucleotides were
introduced into the clone 76 cells by liposome-mediated trans-
fection.
The CDRDON containing an AUG initiation codon se-
quence as the target of PB2 (CDRDON-PB2-as) had the high-
est inhibitory e¡ect, causing more than 50% inhibition at a 0.3
WM concentration (Table 2). The CDRDON-PA-as and NP-
as, containing the AUG initiation codon sequence targeted to
PA and NP, showed 26% and 30% inhibition of CAT protein
expression at a 0.3 WM concentration. In contrast, the
CDRDON-PB1-as, containing the AUG initiation codon tar-
geted to PB1, showed lower anti-CAT activity at a 0.3 WM
concentration (Table 2). As control sequences, the random
oligonucleotides showed no inhibitory e¡ects on the target
AUG initiation codon. Furthermore, the circular dumbbell
RNA/DNA chimeric oligonucleotides, CDRDON-PB2-as,
CDRDON-PB1-as, CDRDON-PA-as, and CDRDON-NP-
as, showed increased inhibition e⁄ciency with an increase in
the dumbbell RNA/DNA chimeric oligonucleotides (Table 2).
These results suggest that the circular dumbbell RNA/DNA
chimeric oligonucleotides conferred sequence-speci¢c inhibi-
tion (Table 2). On the other hand, the phosphorothioate oli-
godeoxynucleotide (S-ODN-PB2-as) containing an AUG ini-
tiation codon sequence as the target of PBs was chosen for
comparison with the CDRDON-PB2-as. The CDRDON-PB2-
as showed higher inhibitory activity than S-ODN-PB2-as (Ta-
ble 2) [33]. The phosphorothioate analogues have also been
studied for their antiviral properties against in£uenza virus A
[34]. The phosphorothioate analogues inhibited the replication
of in£uenza virus A in a dose-dependent manner, and had no
sequence-speci¢c inhibition. In our experiment, sequence-spe-
ci¢c inhibition could be obtained with in£uenza virus A by the
circular dumbbell RNA/DNA chimeric oligonucleotides.
The circular dumbbell RNA/DNA chimeric oligonucleotide
showed increased nuclease resistance and oligonucleotide up-
take into cells, as compared with the nicked dumbbell RNA/
DNA chimeric oligonucleotide and the linear antisense phos-
phodiester. Of particular interest, the antisense phosphodiest-
er oligodeoxynucleotide is liberated together with the RNA
cleavage product by RNase H treatment of the dumbbell
RNA/DNA chimeric oligonucleotides. The liberated antisense
phosphodiester deoxyoligonucleotide was bound to the target
mRNA, which gave mRNA cleavage products upon the treat-
ment with RNase H. In fact, circular dumbbell RNA/DNA
chimeric oligonucleotides with four target sites (in£uenza vi-
rus A RNA polymerases (PB1, PB2, PA) and nucleoprotein
(NP)) were synthesized and tested for inhibitory e¡ects by a
CAT-ELISA assay using the clone 76 cell line. The
CDRDON-PB2-as containing an AUG initiation codon se-
quence as the target of PB2 showed highly inhibitory e¡ects.
That is to say, when the circular dumbbell RNA/DNA chi-
meric oligonucleotide is directly delivered into animal cells or
virus-infected cells, its antisense phosphodiester oligodeoxynu-
cleotide function appears. The limited toxicity of unmodi¢ed
phosphodiester oligonucleotides and the sequence-speci¢c
binding to target mRNA indicate that circular dumbbell
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Fig. 4. Cellular uptake of the 32P-labeled-CDRDON and
NDRDON. The MOLT-4 cells were incubated with the 32P-labeled
anti-ODN (a), the 32P-labeled NDRDON (E), the 32P-labeled
CDRDON (F), and the 32P-labeled anti-S-ODN (b) at 37‡C for
various times. Cell-associated radioactivity was determined as de-
scribed in Section 2. Experiments were carried out in triplicate and
the data represent average values and standard deviations.
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RNA/DNA chimeric phosphodiester oligonucleotide can be
used with intact cells, and may prevent viral development in
culture.
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